179 related articles for article (PubMed ID: 24732011)
21. The role of the Type I interferon response in the resistance of mice to filovirus infection.
Bray M
J Gen Virol; 2001 Jun; 82(Pt 6):1365-1373. PubMed ID: 11369881
[TBL] [Abstract][Full Text] [Related]
22. Filovirus research: knowledge expands to meet a growing threat.
Bray M; Murphy FA
J Infect Dis; 2007 Nov; 196 Suppl 2():S438-43. PubMed ID: 17940981
[No Abstract] [Full Text] [Related]
23. Repurposing potential of 1st generation H
Schafer A; Cheng H; Xiong R; Soloveva V; Retterer C; Mo F; Bavari S; Thatcher G; Rong L
Antiviral Res; 2018 Sep; 157():47-56. PubMed ID: 29981374
[TBL] [Abstract][Full Text] [Related]
24. Protocol for testing filovirus treatments during outbreaks.
Nakkazi E
Lancet Infect Dis; 2024 May; 24(5):e283. PubMed ID: 38677311
[No Abstract] [Full Text] [Related]
25. Retro-2 and its dihydroquinazolinone derivatives inhibit filovirus infection.
Shtanko O; Sakurai Y; Reyes AN; Noël R; Cintrat JC; Gillet D; Barbier J; Davey RA
Antiviral Res; 2018 Jan; 149():154-163. PubMed ID: 29175127
[TBL] [Abstract][Full Text] [Related]
26. Filovirus hemorrhagic fever outbreak case management: a review of current and future treatment options.
Roddy P; Colebunders R; Jeffs B; Palma PP; Van Herp M; Borchert M
J Infect Dis; 2011 Nov; 204 Suppl 3():S791-5. PubMed ID: 21987752
[TBL] [Abstract][Full Text] [Related]
27. Advances in virus-like particle vaccines for filoviruses.
Warfield KL; Aman MJ
J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1053-9. PubMed ID: 21987741
[TBL] [Abstract][Full Text] [Related]
28. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses.
Eyer L; Zouharová D; Širmarová J; Fojtíková M; Štefánik M; Haviernik J; Nencka R; de Clercq E; Růžek D
Antiviral Res; 2017 Jun; 142():63-67. PubMed ID: 28336346
[TBL] [Abstract][Full Text] [Related]
29. Advanced antisense therapies for postexposure protection against lethal filovirus infections.
Warren TK; Warfield KL; Wells J; Swenson DL; Donner KS; Van Tongeren SA; Garza NL; Dong L; Mourich DV; Crumley S; Nichols DK; Iversen PL; Bavari S
Nat Med; 2010 Sep; 16(9):991-4. PubMed ID: 20729866
[TBL] [Abstract][Full Text] [Related]
30. Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir.
Comer JE; Escaffre O; Neef N; Brasel T; Juelich TL; Smith JK; Smith J; Kalveram B; Perez DD; Massey S; Zhang L; Freiberg AN
Viruses; 2019 Feb; 11(2):. PubMed ID: 30717492
[TBL] [Abstract][Full Text] [Related]
31. No exit: targeting the budding process to inhibit filovirus replication.
Harty RN
Antiviral Res; 2009 Mar; 81(3):189-97. PubMed ID: 19114059
[TBL] [Abstract][Full Text] [Related]
32. Post-exposure therapy of filovirus infections.
Wong G; Qiu X; Olinger GG; Kobinger GP
Trends Microbiol; 2014 Aug; 22(8):456-63. PubMed ID: 24794572
[TBL] [Abstract][Full Text] [Related]
33. Treatment-focused Ebola trials, supportive care and future of filovirus care.
Keshtkar-Jahromi M; Martins KAO; Cardile AP; Reisler RB; Christopher GW; Bavari S
Expert Rev Anti Infect Ther; 2018 Jan; 16(1):67-76. PubMed ID: 29210303
[TBL] [Abstract][Full Text] [Related]
34. Small animal models of filovirus disease: recent advances and future directions.
Cross RW; Fenton KA; Geisbert TW
Expert Opin Drug Discov; 2018 Nov; 13(11):1027-1040. PubMed ID: 30269599
[TBL] [Abstract][Full Text] [Related]
35. Rapid molecular strategy for filovirus detection and characterization.
Zhai J; Palacios G; Towner JS; Jabado O; Kapoor V; Venter M; Grolla A; Briese T; Paweska J; Swanepoel R; Feldmann H; Nichol ST; Lipkin WI
J Clin Microbiol; 2007 Jan; 45(1):224-6. PubMed ID: 17079496
[TBL] [Abstract][Full Text] [Related]
36. A review of filovirus work and facilities at the Defence Science and Technology Laboratory Porton Down.
Smither SJ; Lever MS
Viruses; 2012 Aug; 4(8):1305-17. PubMed ID: 23012627
[TBL] [Abstract][Full Text] [Related]
37. Filoviruses Infect Rhesus Macaque Synoviocytes in Vivo and Primary Human Synoviocytes in Vitro.
Cooper TK; Logue J; Liu DX; Perry DL; Hart RJ; Hischak AMW; Bernbaum JG; Gerhardt DM; Rojas O; Bohannon JK; Hagen KR; Johnson RF; Crozier I; Jahrling PB; Hensley LE; Bennett RS
Am J Pathol; 2020 Sep; 190(9):1867-1880. PubMed ID: 32479821
[TBL] [Abstract][Full Text] [Related]
38. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.
Dye JM; Herbert AS; Kuehne AI; Barth JF; Muhammad MA; Zak SE; Ortiz RA; Prugar LI; Pratt WD
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5034-9. PubMed ID: 22411795
[TBL] [Abstract][Full Text] [Related]
39. Animal models for filovirus infections.
Siragam V; Wong G; Qiu XG
Zool Res; 2018 Jan; 39(1):15-24. PubMed ID: 29511141
[TBL] [Abstract][Full Text] [Related]
40. Intracellular events and cell fate in filovirus infection.
Olejnik J; Ryabchikova E; Corley RB; Mühlberger E
Viruses; 2011 Aug; 3(8):1501-31. PubMed ID: 21927676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
